Year: 2015
Type: article
Abstract: BACKGROUND/AIMS: Large epidemiological prospective studies represent an important opportunity for investigating risk factors for rare diseases such as Parkinson's disease (PD). Here we describe the procedures we used for ascertaining PD cases in the EPIC (European Prospective Investigation into Cancer and Nutrition) study. METHODS: The following three-phase procedure was used: (1) elaboration of a NeuroEPIC4PD template for clinical data collection, (2) identification of all potential PD cases via record linkage and (3) validation of the diagnosis through clinical record revision, in a population of 220,494 subjects recruited in 7 European countries. All cases were labelled with the NeuroEPIC4PD diagnoses of 'definite', 'very likely', 'probable', or 'possible' PD. RESULTS: A total of 881 PD cases were identified, with over 2,741,780 person-years of follow-up (199 definite, 275 very likely, 146 probable, and 261 possible). Of these, 734 were incident cases. The mean age at diagnosis was 67.9 years (SD 9.2) and 458 patients (52.0%) were men. Bradykinesia was the most frequent presenting motor sign (76.5%). Tremor-dominant and akinetic rigid forms of PD were the most common types of PD. A total of 289 patients (32.8%) were dead at the time of the last follow-up. CONCLUSIONS: This exercise proved that it is feasible to ascertain PD in large population-based cohort studies and offers a potential framework to be replicated in similar studies.
Source: Neurodegenerative Diseases
DOI: 10.1159/000381857
Authors: Valentina Gallo, Carol Brayne, Lars Forsgren, Roger A. Barker, Jesper Petersson, Oskar Hansson, Daniel Lindqvist, Claudio Ruffmann, Lianna Ishihara, Robert Luben, Larraitz Arriola, Alberto Bergareche, Diana Gavrila, Maria Elena Erro, Nicola Vanacore, Carlotta Sacerdote, Bas Bueno-de-Mesquita, Roel Vermeulen, Meinie Seelen, Sabina Sieri, Giovanna Masala, Silvia Ramat, Andreas Kyrozis, Antonia Thricopolou, Salvatore Panico, Amalia Mattiello, Rudolf Kaaks, Birgit Teucher, Verena Katzke, Manja Kloss, Lisa Curry, Federico Calboli, Elio Riboli, Paolo Vineis, Lefkos Middleton
Institutions: Imperial College London, University of Cambridge, Umeå University, Lund University, Istituti Clinici di Perfezionamento, GlaxoSmithKline (United Kingdom), Basque Government, Biogipuzkoa Health Research Institute, Donostiako Unibertsitate Ospitalea, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Biomedical Research Networking Center on Neurodegenerative Diseases, Centro de Investigación Biomédica en Red, Complejo Hospitalario de Navarra, Istituto Superiore di Sanità, Italian institute for Genomic Medicine, Piedmont Reference Center for Epidemiology and Cancer Prevention, University of Malaya, National Institute for Public Health and the Environment, Utrecht University, University Medical Center Utrecht, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto per lo Studio e la Prevenzione Oncologica, Azienda Ospedaliero-Universitaria Careggi, National and Kapodistrian University of Athens, Hellenic Health Foundation, Federico II University Hospital, University of Naples Federico II, German Cancer Research Center, Heidelberg University
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Compagnia di San Paolo, Deutsches Krebsforschungszentrum, Wellcome Trust, Institute for Scientific Interchange, Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, European Commission, Institut National de la Santé et de la Recherche Médicale, Bundesministerium für Bildung und Forschung, Ligue Contre le Cancer, Associazione Italiana per la Ricerca sul Cancro, Norges Forskningsråd, Deutsche Krebshilfe, Medical Research Council, World Cancer Research Fund, Instituto de Salud Carlos III
OpenAlex ID: W1782794043